Cardiology Unit, Azienda Ospedaliero-Universitaria di Ferrara, Cona (Ferrara), Italy.
Unit of Medical Genetics, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Heart Rhythm. 2024 Aug;21(8):1363-1369. doi: 10.1016/j.hrthm.2024.03.008. Epub 2024 Mar 10.
Cardiac conduction disorder (CCD) in patients <50 years old is a rare and mostly unknown condition.
We aimed to assess clinical characteristics and genetic background of patients <50 years old with CCD of unknown origin.
We retrospectively reviewed a consecutive series of patients with a diagnosis of CCD before the age of 50 years referred to our center between January 2019 and December 2021. Patients underwent complete clinical examination and genetic evaluation.
We enrolled 39 patients with a median age of 40 years (28-47 years) at the onset of symptoms. A cardiac implantable electronic device was implanted in 69% of the patients. In 15 of 39 CCD index patients (38%), we found a total of 13 different gene variations (3 pathogenic, 6 likely pathogenic, and 4 variants of uncertain significance), mostly in 3 genes (SCN5A, TRPM4, and LMNA). In our cohort, genetic testing led to the decision to implant an implantable cardioverter-defibrillator in 2 patients for the increased risk of sudden cardiac death.
Patients with the occurrence of CCD before the age of 50 years present with a high rate of pathologic gene variations, mostly in 3 genes (SCN5A, TRPM4, and LMNA). The presence of pathogenic variations may add information about the prognosis and lead to an individualized therapeutic approach.
50 岁以下的心脏传导障碍(CCD)是一种罕见且大多未知的疾病。
我们旨在评估 50 岁以下原因不明的 CCD 患者的临床特征和遗传背景。
我们回顾性分析了 2019 年 1 月至 2021 年 12 月期间我院连续收治的 39 例诊断为 50 岁以下 CCD 的患者。患者接受了完整的临床检查和基因评估。
我们纳入了 39 例中位年龄为 40 岁(28-47 岁)的患者,这些患者的症状首发年龄均在 50 岁之前。69%的患者植入了心脏植入式电子设备。在 39 例 CCD 指数患者中的 15 例(38%)中,我们共发现了 13 种不同的基因突变(3 种致病性、6 种可能致病性和 4 种意义不明的变异),这些基因突变主要发生在 3 个基因(SCN5A、TRPM4 和 LMNA)中。在我们的队列中,基因检测导致 2 名患者决定植入植入式心脏复律除颤器,以增加发生心源性猝死的风险。
50 岁以下发生 CCD 的患者存在较高的病理性基因突变率,主要发生在 3 个基因(SCN5A、TRPM4 和 LMNA)中。致病性变异的存在可能会增加预后信息,并导致个体化的治疗方法。